Status:
ACTIVE_NOT_RECRUITING
Individualized Brain Stimulation to Improve Mobility in Alzheimer's Disease
Lead Sponsor:
Hebrew SeniorLife
Conditions:
Alzheimer Dementia
Presenile Alzheimer Dementia
Eligibility:
All Genders
65+ years
Phase:
NA
Brief Summary
The objective of this study is to conduct a pilot, randomized sham-controlled trials to determine the feasibility and effects of a 10-session personalized tDCS intervention targeting the left dorsolat...
Detailed Description
Beyond the profound impact on memory, Alzheimer's disease (AD) neuropathology, even in its early stages, affects the prefrontal lobes leading to executive dysfunction and mobility disturbances. Prefro...
Eligibility Criteria
Inclusion
- Men and women aged 65 and older living within supportive housing facilities
- Mild Alzheimer's disease (AD) defined by the combination of 1) at least mild cognitive impairment defined as a modified TICS score of ≤ 34, 2) informant-report of Instrumental Activities of Daily Living impairment as defined as a score of ≥ 6 on the NACC Functional Activities Questionnaire, and 3) a Clinical Dementia Rating score of 1.
Exclusion
- Inability to secure informant participation
- Unwillingness to cooperate or participate in the study protocol
- An inability to ambulate without the assistance of another person (canes or walkers allowed)
- A clinical history of stroke, Parkinson's disease or parkinsonian symptoms, multiple sclerosis, normal pressure hydrocephalus, or other neurological conditions outside of mild AD.
- Any report of severe lower-extremity arthritis or physician-diagnosis of peripheral neuropathy
- Use of antipsychotics, anti-seizure, benzodiazepines, or other neuroactive medications
- Severe depression defined by a Center for Epidemiologic Studies Depression scale score greater than 16
- Any report of physician-diagnosis of schizophrenia, bipolar disorder, or other psychiatric illness
- Contraindications to MRI or tDCS, including reported seizure within the past two years, use of neuropsychological-active drugs, the risk of metal objects anywhere in the body, self-reported presence of specific implanted medical devices (e.g., deep brain stimulator, medication infusion pump, cochlear implant, pacemakers, etc.), or the presence of any active dermatological condition, such as eczema, on the scalp
Key Trial Info
Start Date :
January 31 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2026
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT04289402
Start Date
January 31 2020
End Date
January 31 2026
Last Update
September 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hebrew Rehabilitation Center
Roslindale, Massachusetts, United States, 02131